Loading organizations...
Sim&Cure develops advanced software solutions for cerebral aneurysm treatment, leveraging digital twin technology and artificial intelligence. Their flagship product, Sim&Size, is a pre-operative planning platform. It empowers medical professionals to simulate and optimize endovascular procedures, enhancing success and patient outcomes through detailed computational modeling.
Founded in 2014 by Mathieu Sanchez, a PhD and former R&D Engineer at Philips Healthcare, Sim&Cure addressed a critical need for precision in neurovascular care. Sanchez applied advanced simulation and AI to transform complex patient data into effective clinical decision-making, improving aneurysm intervention planning.
Healthcare professionals and hospitals globally utilize Sim&Cure's products for cerebral aneurysm treatment. The company’s mission is to advance endovascular neurosurgery by delivering smarter, interconnected solutions supporting evolving treatment methodologies. Sim&Cure empowers physicians with innovative tools, fostering improved patient care and clinical efficiency.
Sim&Cure has raised $3.0M across 1 funding round.
Sim&Cure has raised $3.0M in total across 1 funding round.
Sim&Cure has raised $3.0M in total across 1 funding round.
Sim&Cure's investors include Elaia Partners.
Sim&Cure is a French MedTech company that builds patient‑specific digital‑twin and AI software to plan and simulate endovascular treatment of cerebral aneurysms, aiming to improve physician decision‑making and patient outcomes worldwide[1][5]. The company’s flagship product (Sim&Size) and complementary tools (Sim&Train, Sim&Predict) are used by hospitals and medtech partners and have been deployed across dozens of countries with thousands of treatment‑planning procedures to date[5][2].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick take: Sim&Cure has moved from a clinical simulation prototype to a commercially deployed MedTech software suite with regulatory clearance, notable clinical adoption, and strategic partnerships—positioning it to scale as healthcare increasingly adopts digital‑twin and AI planning tools for complex interventions[5][1].
Sim&Cure has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Series A in May 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2019 | $3.0M Series A | Elaia Partners |